Page 22 - நொதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நொதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நொதி Today - Breaking & Trending Today

New NIH grant supports research on Alzheimer's disease caused by gene mutations


New NIH grant supports research on Alzheimer s disease caused by gene mutations
A new grant from the National Institute On Aging at the National Institutes of Health will support ongoing research at Rensselaer Polytechnic Institute to address Alzheimer s disease caused by gene mutations. According to Chunyu Wang, the principal investigator and an assistant professor of biological sciences at Rensselaer, the project seeks to understand and counter the mechanism that produces Amyloid-Beta 42 peptide in brain cells.
A key pathology in Alzheimer s is accumulation of senile plaque in the brain, which is mainly composed of the Amyloid Beta-42 peptide. This grant supports research into an enzyme that is responsible for producing the toxic peptide using single molecule techniques, and may identify novel mechanisms and targets for future Alzheimer s therapeutics. ....

Chunyu Wang , Emily Henderson , National Institutes Of Health , National Institute On , Rensselaer Polytechnic Institute , Rensselaer Center , National Institute On Aging , National Institutes , Scott Forth , Familial Alzheimer , Amyloid Beta , Alzheimer 39s Disease , எமிலி ஹென்டர்சன் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , தேசிய நிறுவனம் ஆன் , ரென்சீலர் பாலிடெக்நிக் நிறுவனம் , ரென்சீலர் மையம் , தேசிய நிறுவனங்கள் , ஸ்காட் முன்னால் , குடும்ப முதுமறதி ,

First-of-its-kind cardiovascular drug gets FDA approval based on study from Canadian VIGOUR Centre


First-of-its-kind cardiovascular drug gets FDA approval based on study from Canadian VIGOUR Centre
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers at the University of Alberta s Canadian VIGOUR Centre.
As reported in March 2020, vericiguat works by stimulating an enzyme in the body called soluble guanylate cyclase (sGC), which is important for enhancing heart function and helping blood vessels relax to provide better blood flow. In patients with heart failure, sGC is reduced and unable to adequately stimulate cyclic guanosine monophosphate (cGMP), necessary for transmitting chemical signals to blood vessels, which results in vascular and corona ....

Paul Armstrong , Emily Henderson , Bayer Ag , Duke Clinical Research Institute In Durham , University Of Alberta Canadian , Drug Administration , Merck Inc , Duke Clinical Research Institute , Blood Vessels , Heart Failure , பால் ஆம்ஸ்ட்ராங் , எமிலி ஹென்டர்சன் , டியூக் மருத்துவ ஆராய்ச்சி நிறுவனம் இல் டர்ஹாம் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா கனடியன் , மெர்க் இன்க் , டியூக் மருத்துவ ஆராய்ச்சி நிறுவனம் , இரத்தம் நாளங்கள் , இதயம் தோல்வி ,

New drug target valid for breast cancer as well as lymphoma


New drug target valid for breast cancer as well as lymphoma
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
The results provide more justification and rationale for starting the clinical trial in May. It s another exciting stepping stone to finding out if this is going to be a new cancer treatment.
John Mackey, First Author, Professor and Director of Oncology Clinical Trials, Faculty of Medicine & Dentistry, University of Alberta
The drug PCLX-001 is designed to selectively kill cancer cells by targeting enzymes involved in myristoylation, a process key to the cell signaling system that is often defective in cancer cells. The molecule was originally developed by the University of Dundee as a treatment for African sleeping sickness. U of A cell biologist Luc Berthiaume was the first to realize it ....

John Mackey , Luc Berthiaume , Emily Henderson , Cross Cancer Institute In Edmonton , University Of Alberta , Alberta Cancer Foundation , Cure Cancer Foundation , University Of Dundee , Pacylex Pharmaceuticals , Cross Cancer Institute , Cure Cancer , Cancer Treatment , Breast Cancer , Clinical Trial , ஜான் மேக்கி , லூக் பெர்த்தியாம் , எமிலி ஹென்டர்சன் , குறுக்கு புற்றுநோய் நிறுவனம் இல் எட்மண்டன் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , ஆல்பர்ட்டா புற்றுநோய் அடித்தளம் , குணப்படுத்த புற்றுநோய் அடித்தளம் , பல்கலைக்கழகம் ஆஃப் டண்டீ , குறுக்கு புற்றுநோய் நிறுவனம் , குணப்படுத்த புற்றுநோய் , புற்றுநோய் சிகிச்சை , மார்பக புற்றுநோய் ,